Inhibitors of Aurora kinases for the treatment of cancer

被引：11
|
作者：
Fancelli, D [1 ]
Moll, J [1 ]
机构：
[1] BU Oncol, Nerviano Med Sci, I-20014 Nerviano, Italy
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2005年 / 15卷 / 09期
关键词：
Aurora kinase; cancer treatment; inhibitor; mitosis;
D O I：
10.1517/13543776.15.9.1169
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Aurora protein kinases are key players in different steps during mitosis and their activity is required for correct cell division. The inhibition of Aurora kinases is regarded as a promising approach for the development of novel anticancer agents. In the last few years several templates for ATP-competitive kinase inhibition have been successfully developed towards the inhibition of Aurora kinases, and the first compounds have recently entered clinical studies. This review summarises the patent literature up until March 2005 and the characteristics of the low molecular weight Aurora inhibitors described so far.
引用
收藏
页码：1169 / 1182
页数：14
相关论文
共 50 条
  • [41] Aurora kinases A and B and familial breast cancer risk
    Tchatchou, Sandrine
    Wirtenberger, Michael
    Hemminki, Kari
    Sutter, Christian
    Meindl, Alfons
    Wappenschmidt, Barbara
    Kiechle, Marion
    Bugert, Peter
    Schmutzler, Rita K.
    Bartram, Claus R.
    Burwinkel, Barbara
    CANCER LETTERS, 2007, 247 (02) : 266 - 272
  • [42] Aurora B Inhibitors as Cancer Therapeutics
    Kovacs, Antal H.
    Zhao, Dong
    Hou, Jinqiang
    MOLECULES, 2023, 28 (08):
  • [43] GFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence
    Quatrale, Anna Elisa
    Porcelli, Letizia
    Silvestris, Nicola
    Colucci, Giuseppe
    Paradiso, Angelo
    Azzariti, Amalia
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 1962 - 1972
  • [44] Design of dual allosteric inhibitors of MEK and Raf kinases for cancer treatment
    Nesh, Nicholas
    BIOPHYSICAL JOURNAL, 2024, 123 (03) : 429A - 430A
  • [45] Bisubstrate-analogue inhibitors targeting mitotic protein kinases Aurora A and Haspin
    Lavogina, D.
    Kestav, K.
    Enkvist, E.
    Viht, K.
    Raidaru, G.
    Uri, A.
    FEBS JOURNAL, 2015, 282 : 139 - 139
  • [46] Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines
    Baldini, Enke
    Tuccilli, Chiara
    Prinzi, Natalie
    Sorrenti, Salvatore
    Antonelli, Alessandro
    Gnessi, Lucio
    Morrone, Stefania
    Moretti, Costanzo
    Bononi, Marco
    Arlot-Bonnemains, Yannick
    D'Armiento, Massimino
    Ulisse, Salvatore
    ENDOCRINE-RELATED CANCER, 2014, 21 (05) : 797 - 811
  • [47] Aurora kinases: novel anti-breast cancer targets
    Yiliyaer
    Yusufu Maimaiti
    Oncology and Translational Medicine, 2019, 5 (01) : 43 - 48
  • [48] Aurora kinases: new molecular targets in thyroid cancer therapy
    Baldini, E.
    Sorrenti, S.
    D'Armiento, E.
    Prinzi, N.
    Guaitoli, E.
    Favoriti, P.
    Gnessi, L.
    Moretti, C.
    Bianchini, M.
    Alessandrini, S.
    Catania, A.
    De Antoni, E.
    Ulisse, S.
    CLINICA TERAPEUTICA, 2012, 163 (06): : E457 - E462
  • [49] Aurora A, Aurora B, Aurora C and BRAF kinases genes expression in urine samples from patients with prostate cancer
    Mankovska, O.
    Asatryan, O.
    Vikarchuk, M.
    Kononenko, O.
    Stakhovsky, E.
    Kashuba, V.
    FEBS JOURNAL, 2016, 283 : 368 - 368
  • [50] The Aurora kinase inhibitors in cancer research and therapy
    Cicenas, Jonas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (09) : 1995 - 2012
12345